Showing results (1101-1110 of 1,368) with videos related to

Sort By:
Pageof 137
Journal of the Society for Cardiovascular Angiography & Interventions|December 9, 2024
The Role of Cardiac Computed Tomography Angiography in Risk Stratification for Coronary Artery DiseaseSophie E van Rosendael, Arthur Shiyovich, Rhanderson N Cardoso, et al.
Cell Death Discovery|May 16, 2018
Hyperglycemia potentiates a shift from apoptosis to RIP1-dependent necroptosisWilliam D McCaig, Payal S Patel, Sergey A Sosunov, et al.
Plos Pathogens|December 17, 2019
Alpha-defensin 5 differentially modulates adenovirus vaccine vectors from different serotypes in vivoLawrence J Tartaglia, Alexander Badamchi-Zadeh, Peter Abbink, et al.
Neurology|February 17, 2019
A new way to estimate neurologic disease prevalence in the United States: Illustrated with MSLorene M Nelson, Mitchell T Wallin, Ruth Ann Marrie, et al.
Environmental Research|January 28, 2021
Large-scale IgM and IgG SARS-CoV-2 serological screening among healthcare workers with a low infection prevalence based on nasopharyngeal swab tests in an Italian university hospital: Perspectives for public healthLuigi Vimercati, Pasquale Stefanizzi, Luigi De Maria, et al.
Neuro-Oncology|February 17, 2017
The clinical value of patient-derived glioblastoma tumorspheres in predicting treatment responseQuintino Giorgio D'Alessandris, Mauro Biffoni, Maurizio Martini, et al.
JAMA Neurology|May 15, 2023
Population-Based Estimates for the Prevalence of Multiple Sclerosis in the United States by Race, Ethnicity, Age, Sex, and Geographic RegionMichael Hittle, William J Culpepper, Annette Langer-Gould, et al.
Oncotarget|January 19, 2017
Type 5 phosphodiesterase regulates glioblastoma multiforme aggressiveness and clinical outcomeValeriana Cesarini, Maurizio Martini, Lucia Ricci Vitiani, et al.
Future Oncology (London, England)|May 31, 2013
Serum sarcosine is a risk factor for progression and survival in patients with metastatic castration-resistant prostate cancerGiuseppe Lucarelli, Pasquale Ditonno, Carlo Bettocchi, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 10, 2023
Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose AdjustmentAlbert Oriol, Meletios Dimopoulos, Fredrik Schjesvold, et al.
Pageof 137